Last reviewed · How we verify
Conventional OST
Conventional OST (Osteogenic Stem Cell Therapy) promotes bone formation and regeneration by utilizing osteogenic stem cells to stimulate new bone growth.
Conventional OST (Osteogenic Stem Cell Therapy) promotes bone formation and regeneration by utilizing osteogenic stem cells to stimulate new bone growth. Used for Bone defects and fracture healing.
At a glance
| Generic name | Conventional OST |
|---|---|
| Also known as | Control group |
| Sponsor | Taejoon Pharmaceutical Co., Ltd. |
| Drug class | Cell therapy / Regenerative medicine |
| Modality | Small molecule |
| Therapeutic area | Orthopedics / Regenerative Medicine |
| Phase | Phase 3 |
Mechanism of action
This therapy involves the use of osteogenic stem cells that differentiate into bone-forming osteoblasts, promoting endogenous bone regeneration. The stem cells secrete growth factors and extracellular matrix components that facilitate osteogenesis and integration with existing bone tissue. This approach is designed to enhance bone healing in defects or degenerative conditions.
Approved indications
- Bone defects and fracture healing
Common side effects
- Injection site reaction
- Infection
- Immune response
Key clinical trials
- A Phase 3 Clinical Trials for Bowel Preparation for Colonoscopy (PHASE3)
- Testing and Treating Hepatitis C in Community Pharmacies (NA)
- Pilot Trial of Directly Observed Anti HCV Therapy & Contingency Management in a Population on Opiate Substitute Therapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Conventional OST CI brief — competitive landscape report
- Conventional OST updates RSS · CI watch RSS
- Taejoon Pharmaceutical Co., Ltd. portfolio CI